Christopher Ogden - 20 Aug 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Issuer symbol
CTMX
Transactions as of
20 Aug 2024
Net transactions value
-$2,439
Form type
4
Filing time
22 Aug 2024, 17:59:48 UTC
Previous filing
14 Jun 2024
Next filing
06 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +6,875 +6.7% $0.000000 110,061 20 Aug 2024 Direct F1, F2
transaction CTMX Common Stock Sale $2,439 -1,984 -1.8% $1.23 108,077 20 Aug 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units (PSUs) Options Exercise $0 -6,875 -100% $0.000000 0 20 Aug 2024 Common Stock 6,875 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2 Includes 77,810 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
F4 Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.